These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31442005)

  • 21. Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.
    Takahashi B; Funami H; Iwaki T; Maruoka H; Shibata M; Koyama M; Nagahira A; Kamiide Y; Kanki S; Igawa Y; Muto T
    Bioorg Med Chem; 2015 Aug; 23(15):4792-4803. PubMed ID: 26100441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of the ghrelin receptor is described by a privileged collective motion: a model for constitutive and agonist-induced activation of a sub-class A G-protein coupled receptor (GPCR).
    Floquet N; M'Kadmi C; Perahia D; Gagne D; Bergé G; Marie J; Banères JL; Galleyrand JC; Fehrentz JA; Martinez J
    J Mol Biol; 2010 Jan; 395(4):769-84. PubMed ID: 19782690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease.
    Abegg K; Bernasconi L; Hutter M; Whiting L; Pietra C; Giuliano C; Lutz TA; Riediger T
    Diabetes Obes Metab; 2017 Dec; 19(12):1740-1750. PubMed ID: 28544245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.
    Kong J; Chuddy J; Stock IA; Loria PM; Straub SV; Vage C; Cameron KO; Bhattacharya SK; Lapham K; McClure KF; Zhang Y; Jackson VM
    Br J Pharmacol; 2016 May; 173(9):1452-64. PubMed ID: 26784385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo characterization of high Basal signaling from the ghrelin receptor.
    Petersen PS; Woldbye DP; Madsen AN; Egerod KL; Jin C; Lang M; Rasmussen M; Beck-Sickinger AG; Holst B
    Endocrinology; 2009 Nov; 150(11):4920-30. PubMed ID: 19819980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ghrelin receptor modulators: a patent review (2011 - 2014).
    Costantino L; Barlocco D
    Expert Opin Ther Pat; 2014 Sep; 24(9):1007-19. PubMed ID: 25047815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Optimization of Ghrelin Receptor Inverse Agonists to Improve Lipophilicity and Avoid Mechanism-Based CYP3A4 Inactivation.
    Takahashi B; Funami H; Shibata M; Maruoka H; Koyama M; Kanki S; Muto T
    Chem Pharm Bull (Tokyo); 2015; 63(10):825-32. PubMed ID: 26423040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor.
    McClure KF; Jackson M; Cameron KO; Kung DW; Perry DA; Orr ST; Zhang Y; Kohrt J; Tu M; Gao H; Fernando D; Jones R; Erasga N; Wang G; Polivkova J; Jiao W; Swartz R; Ueno H; Bhattacharya SK; Stock IA; Varma S; Bagdasarian V; Perez S; Kelly-Sullivan D; Wang R; Kong J; Cornelius P; Michael L; Lee E; Janssen A; Steyn SJ; Lapham K; Goosen T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5410-4. PubMed ID: 23953189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ghrelin receptor modulators and their therapeutic potential.
    Costantino L; Barlocco D
    Future Med Chem; 2009 Apr; 1(1):157-77. PubMed ID: 21426074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2.
    Carra' G; Calo' G; Spagnolo B; Guerrini R; Arduin M; Marzola E; Trapella C; Regoli D; Salvadori S
    J Pept Res; 2005 Jul; 66(1):39-47. PubMed ID: 15946194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor.
    Takahashi B; Funami H; Iwaki T; Maruoka H; Nagahira A; Koyama M; Kamiide Y; Matsuo T; Muto T; Annoura H
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2707-12. PubMed ID: 25981690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays.
    Bonner GG; Davis P; Stropova D; Edsall S; Yamamura HI; Porreca F; Hruby VJ
    J Med Chem; 2000 Feb; 43(4):569-80. PubMed ID: 10691683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold.
    Haj Salah KB; Maingot M; Blayo AL; M'Kadmi C; Damian M; Mary S; Cantel S; Neasta J; Oiry C; Péraldi-Roux S; Fernandez G; Romero GG; Perello M; Marie J; Banères JL; Fehrentz JA; Denoyelle S
    J Med Chem; 2020 Oct; 63(19):10796-10815. PubMed ID: 32882134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats.
    Morozumi N; Hanada T; Habara H; Yamaki A; Furuya M; Nakatsuka T; Inomata N; Minamitake Y; Ohsuye K; Kangawa K
    Peptides; 2011 May; 32(5):1001-7. PubMed ID: 21291937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorine and rhenium substituted ghrelin analogues as potential imaging probes for the growth hormone secretagogue receptor.
    Rosita D; Dewit MA; Luyt LG
    J Med Chem; 2009 Apr; 52(8):2196-203. PubMed ID: 19323558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and optimization of (R)-prolinol-derived agonists of the Growth Hormone Secretagogue receptor (GHSR).
    Zhai W; Flynn N; Longhi DA; Tino JA; Murphy BJ; Slusarchyk D; Gordon DA; Pendri A; Shi S; Stoffel R; Ma B; Sofia MJ; Gerritz SW
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5083-6. PubMed ID: 18722770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aza-amino acid scanning of secondary structure suited for solid-phase peptide synthesis with fmoc chemistry and aza-amino acids with heteroatomic side chains.
    Boeglin D; Lubell WD
    J Comb Chem; 2005; 7(6):864-78. PubMed ID: 16283795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists.
    Charoenthongtrakul S; Giuliana D; Longo KA; Govek EK; Nolan A; Gagne S; Morgan K; Hixon J; Flynn N; Murphy BJ; Hernández AS; Li J; Tino JA; Gordon DA; DiStefano PS; Geddes BJ
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1178-86. PubMed ID: 19252061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational design of dual peptides targeting ghrelin and Y2 receptors to regulate food intake and body weight.
    Kilian TM; Klöting N; Bergmann R; Els-Heindl S; Babilon S; Clément-Ziza M; Zhang Y; Beck-Sickinger AG; Chollet C
    J Med Chem; 2015 May; 58(10):4180-93. PubMed ID: 25905598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational Design, Synthesis, and Pharmacological Characterization of Novel Ghrelin Receptor Inverse Agonists as Potential Treatment against Obesity-Related Metabolic Diseases.
    Daina A; Giuliano C; Pietra C; Wang J; Chi Y; Zou Z; Li F; Yan Z; Zhou Y; Guainazzi A; Garcia Rubio S; Zoete V
    J Med Chem; 2018 Dec; 61(24):11039-11060. PubMed ID: 30265805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.